Literature DB >> 852498

First pass hydroxylation of nortriptyline: concentrations of parent drug and major metabolites in plasma.

G Alván, O Borga, M Lind, L Palmér, B Siwers.   

Abstract

Nortriptyline was given orally and intramuscularly to six depressed patients. Plasma concentrations of parent drug and the unconjugated and conjugated principal metabolite, 10-hydroxynortriptyline, were determined by mass fragmentography. There was a significant decrease in the area under the nortriptyling plasma concentration- time curve after the oral route of administration, whilst the elimination rate was unchanged. With the oral dose, plasma concentrations of the metabolites were higher and peaked earlier than after intramuscular administration, whilst the opposite was true for the parent compound. This proves that the difference in bioavailability between the two routes of administration was due to first pass metabolism. As determined from the ratio between corresponding areas, the relative bioavailability of the oral dose was 66 +-21 S.D. per cent. This fraction is higher than that reported previously when intravenous nortriptyline was used as the reference dosage form.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 852498     DOI: 10.1007/BF00606414

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

1.  Comparison of observed and predicted bioavailability of nortriptyline in humans following oral administration.

Authors:  M Gibaldi
Journal:  J Pharm Sci       Date:  1975-06       Impact factor: 3.534

2.  Importance of "first-pass elimination" for interindividual differences in steady-state concentrations of the adrenergic beta-receptor antagonist alprenolol.

Authors:  G Alván; M Lind; B Mellström; C von Bahr
Journal:  J Pharmacokinet Biopharm       Date:  1977-06

3.  Simultaneous determination of portal vein and hepatic artery blood flow by indicator dilution technique in awake man. Preliminary report.

Authors:  T Strandell; R Erwald; K G Kulling; P Lundbergh; O Marions; K L Wiechel
Journal:  Acta Med Scand       Date:  1972 Jan-Feb

4.  Clearance and biologic half-life as indices of intrinsic hepatic metabolism.

Authors:  D Perrier; M Gibaldi
Journal:  J Pharmacol Exp Ther       Date:  1974-10       Impact factor: 4.030

5.  Pharmacokinetics of nortriptyline in man after single and multiple oral doses: the predictability of steady-state plasma concentrations from single-dose plasma-level data.

Authors:  B Alexanderson
Journal:  Eur J Clin Pharmacol       Date:  1972-03       Impact factor: 2.953

6.  Influence of route of administration on drug availability.

Authors:  M Rowland
Journal:  J Pharm Sci       Date:  1972-01       Impact factor: 3.534

7.  Plasma propranolol levels in adults with observations in four children.

Authors:  D G Shand; E M Nuckolls; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.875

8.  Influence of the route of administration on the area under the plasma concentration-time curve.

Authors:  P A Harris; S Riegelman
Journal:  J Pharm Sci       Date:  1969-01       Impact factor: 3.534

9.  [Treatment of acute poisoning. 3. Pharmacokinetic treatment principals].

Authors:  G Alván; F Sjöqvist
Journal:  Lakartidningen       Date:  1971-03-29

10.  First-pass metabolism of imipramine in man.

Authors:  L F Gram; J Christiansen
Journal:  Clin Pharmacol Ther       Date:  1975-05       Impact factor: 6.875

View more
  23 in total

1.  Importance of "first-pass elimination" for interindividual differences in steady-state concentrations of the adrenergic beta-receptor antagonist alprenolol.

Authors:  G Alván; M Lind; B Mellström; C von Bahr
Journal:  J Pharmacokinet Biopharm       Date:  1977-06

Review 2.  Individual differences in the disposition of drugs metabolised in the body.

Authors:  G Alvan
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

3.  Mean time and first-pass metabolism.

Authors:  D Brockmeier; J Ostrowski
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 4.  Pharmacokinetic optimisation of tricyclic antidepressant therapy.

Authors:  M Furlanut; P Benetello; E Spina
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

Review 5.  The Role of Metabolites of Antidepressants in the Treatment of Depression.

Authors:  M V Rudorfer; W Z Potter
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

6.  First pass effect of pinazepam in the rabbit liver.

Authors:  G M Pacifici; G F Placidi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982       Impact factor: 2.441

Review 7.  Current antidepressant drugs: their clinical use.

Authors:  L E Hollister
Journal:  Drugs       Date:  1981-08       Impact factor: 9.546

8.  The pharmacokinetics and bioavailability of a tracer dose of [3H]-mebendazole in man.

Authors:  M Dawson; P A Braithwaite; M S Roberts; T R Watson
Journal:  Br J Clin Pharmacol       Date:  1985-01       Impact factor: 4.335

9.  Clinical pharmacokinetics of dothiepin. Single-dose kinetics in patients and prediction of steady-state concentrations.

Authors:  K P Maguire; T R Norman; I McIntyre; G D Burrows
Journal:  Clin Pharmacokinet       Date:  1983 Mar-Apr       Impact factor: 6.447

10.  Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6--an evaluation with the nonparametric maximum likelihood method.

Authors:  M Jerling; Y Merlé; F Mentré; A Mallet
Journal:  Br J Clin Pharmacol       Date:  1994-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.